InflaRx (IFRX) Return on Assets Growth (5y) (2022 - 2026)
InflaRx (IFRX) Return on Assets Growth (5y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 336,759.00 |
| Dec 31, 2025 | 426,048.00 |
| Sep 30, 2025 | 485,799.00 |
| Jun 30, 2025 | 471,675.00 |
| Mar 31, 2025 | 435,083.00 |
| Dec 31, 2024 | 387,177.00 |
| Sep 30, 2024 | 212,122.00 |
| Jun 30, 2024 | 200,450.00 |
| Mar 31, 2024 | 189,869.00 |
| Dec 31, 2023 | 182,057.00 |
| Sep 30, 2023 | 146,683.00 |
| Jun 30, 2023 | 167,663.00 |
| Mar 31, 2023 | 197,464.00 |
| Dec 31, 2022 | 327,151.00 |